Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
News|Slideshows|March 25, 2021
8 Neuropsychiatric Symptoms and Treatments of Huntington Disease
In approximately half of patients with Huntington disease, symptoms of depression, irritability/aggression, executive dysfunction, psychosis, cognitive decline, and dementia present long before progressive motor symptoms.
Advertisement
Advertisement
Related to this article
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
Cardiologist Mary Branch, MD, reveals how depression, meds, and food insecurity shape heart risk—and why cardiology-psychiatry teamwork matters.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
What Makes Us Human? The Role of Psychiatry and the Future DSM
5